Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Positive Data in Phase 1 Amira Study

May 2, 2011 10:59 am | News | Comments

Amira Pharmaceuticals, Inc. announced initial positive data from a Phase 1 clinical study of AM152, an oral, selective antagonist of the LPA1 receptor. This study positions Amira to initiate a Phase 2a trial in patients suffering from systemic sclerosis.

TOPICS:

XEN402 Relieves Pain in PHN Trial

May 2, 2011 10:55 am | News | Comments

Xenon Pharmaceuticals Inc. announced that its novel ointment XEN402 demonstrated significant and clinically meaningful reductions in pain in patients with postherpetic neuralgia.

TOPICS:

Abbott Granted New Andogel Approval

May 2, 2011 10:51 am | by Matthew Perrone | News | Comments

Abbott Laboratories said that it received U.S. regulatory approval for a new, more potent formulation of its testosterone gel. The gel is approved for men with hypogonadism or low testosterone.

TOPICS:
Advertisement

FDA Approves Nexium for Infants

May 2, 2011 10:48 am | News | Comments

British drugmaker AstraZeneca PLC said that U.S. regulators approved an injectable version of its heartburn drug Nexium for use in infants as young as a month old.

TOPICS:

Fitch May Downgrade J & J Rating

May 2, 2011 10:46 am | News | Comments

Fitch Ratings said it is considering downgrading certain ratings for Johnson & Johnson, citing the company's move to buy Swiss medical device maker Synthes Inc. for $21.3 billion.

TOPICS:

No More Zerenex Trials Needed

May 2, 2011 10:43 am | News | Comments

Keryx Biopharmaceuticals Inc. said it was informed by a European Union advisory committee that if its current late-stage clinical trial is successful, that study would provide enough data to support a marketing application in the EU

TOPICS:

Watson Selling Generic Concerta

May 2, 2011 10:40 am | News | Comments

Watson Pharmaceuticals Inc. said it has started selling an authorized generic version of Johnson & Johnson's attention deficit hyperactivity disorder drug Concerta. Watson said sales of Concerta, or methylphenidate, totaled $1.5 billion in the last year.

TOPICS:

Teva to Buy Cephalon for $6.8B

May 2, 2011 10:38 am | by Damien Troise | News | Comments

Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion in a deal that would give the world's largest generic drug developer a range of biotechnology drugs aimed at cancer and other conditions.

TOPICS:
Advertisement

Particle Imager Upgrades

May 2, 2011 8:05 am | Product Releases | Comments

A technology upgrade service from Fluid Imaging Technologies enables FlowCAM particle imaging and analysis system users to install many of the company’s latest advances on their existing models.

TOPICS:

Nanoparticle Characterization System

May 2, 2011 8:03 am | Product Releases | Comments

NanoSight announced the release of their latest NS200 nanoparticle characterization system, which features a high sensitivity camera built into the housing of the system.

TOPICS:

Reference Standards

May 2, 2011 8:00 am | Product Releases | Comments

Whitehouse Scientific offers a paper reviewing the development of reference standards over three decades.

TOPICS:

QB3, Deloitte Collaborate On Bioscience Innovation

May 2, 2011 7:57 am | News | Comments

The California Institute for Quantitative Biosciences (QB3) has entered into a collaboration with Deloitte to help the institute in its efforts to convert bioscience innovation into a driver for jobs, companies and improved health in California.

TOPICS:

Acura Pharma CEO Andrew Reddick Has Died

May 2, 2011 7:54 am | News | Comments

Acura Pharmaceuticals Inc. said that President and CEO Andrew Reddick died Thursday. He was 58.

TOPICS:

QRxPharma Completes Enrollment of Phase 3 Safety Study

May 2, 2011 7:50 am | News | Comments

QRxPharma Limited has completed patient enrolment for Study 022, a Phase 3 trial comparing the tolerability and safety profile of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone alone.

TOPICS:

First-In-Human Dosing Commenced in Alzheimer’s Trial

May 2, 2011 7:48 am | News | Comments

Anavex Life Sciences Corp. announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading